Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.30 |
| ▸ | AHR | P35869 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | KIT | P10721 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27805081 | 0.80 | BRD4 (0.36) | MAPTALDH1A1 | |
| SCHEMBL14223672 | 0.78 | CYP1A2 (0.36) | CYP1A2SMN1; SMN2KIT | |
| SCHEMBL3121390 | 0.77 | ALDH1A1 (0.35) | CYP1A2ALDH1A1SMN1; SMN2 | |
| SCHEMBL5148651 | 0.75 | CYP1A2 (0.36) | CYP1A2MAPTALDH1A1NR1I2AHR | |
| SCHEMBL5494790 | 0.74 | KAT2B (0.37) | — | |
| SCHEMBL13809854 | 0.72 | CYP1A2 (0.32) | CYP1A2KIT | |
| SCHEMBL27639661 | 0.72 | TSHR (0.51) | CYP1A2MAPTALDH1A1SMN1; SMN2KIT | |
| SCHEMBL33881 | 0.71 | CYP1A2 (0.42) | CYP1A2MAPTALDH1A1NR1I2AHR | |
| SCHEMBL4199889 | 0.70 | GAA (0.32) | — | |
| SCHEMBL7108391 | 0.70 | KDM4E (0.41) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556389-B9 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2015-09-09 | — | — | EP | disclosed |
| EP-1556389-B3 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2015-04-01 | — | — | EP | disclosed |
| CN-103772284-A | Method for preparing 4,5-diamido-1-(2-ethoxy) pyrazol sulfate | SHENYANG RES INST OF PHOTOGRAPHIC MATERIALS & CHEMICAL INDUSTRY | 2014-05-07 | — | — | CN | disclosed |
| EP-1556389-B1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2007-07-25 | — | — | EP | disclosed |
| US-20070037786-A1 | Cephem compounds | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| US-7129232-B2 | For therapy of of infectious diseases | ASTELLAS PHARMA INC. (JP) | 2006-10-31 | — | — | US | disclosed |
| EP-1556389-A1 | CEPHEM COMPOUNDS | Astellas Pharma Inc. (JP) | 2005-07-27 | — | — | EP | disclosed |
| US-20040132994-A1 | Cephem compounds | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2004-07-08 | — | — | US | disclosed |
| WO-2004039814-A1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037786-A1 | Cephem compounds | CEP170, ABCB11, SLC7A1 | CYP1A2 315/4885MAPT 2537/4885ALDH1A1 1158/4885 |
| US-20040132994-A1 | Cephem compounds | CEP170, ABCB11, RCC2 | CYP1A2 443/4885MAPT 3238/4885ALDH1A1 908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.